Variable response of hidradenitis suppurativa to infliximab in four patients [3]

Clinical and Experimental Dermatology

Volumn 32, Issue 2, 2007, Pages 204-205

  Usmani, N ^a   Clayton, T H ^a   Everett, S ^a   Goodfield, M D J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; CLARITHROMYCIN; CYCLOSPORIN A; DIANE; ETANERCEPT; FUSIDIC ACID; INFLIXIMAB; MINOCYCLINE; PREDNISOLONE; RIFAMPICIN; TACROLIMUS;

ADULT; ALOPECIA; ARTHRALGIA; CASE REPORT; CLINICAL FEATURE; COLON CROHN DISEASE; DISEASE COURSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LETTER; LUPUS LIKE SYNDROME; MALE; PRIORITY JOURNAL; SUPPURATIVE HIDRADENITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33846902650     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2006.02272.x     Document Type: Letter

References (4)

1. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Derm Treatment 2005; 16: 58-61.
2. Adams DR, Gordon KB, Devenyi A, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-2.
3. Sullivan TP, Welsh E, Kerdel FA et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-9.
4. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNF alpha: findings in open label and randomised placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.